New York State Teachers Retirement System Reduces Holdings in Artivion, Inc. (NYSE:AORT)

New York State Teachers Retirement System lessened its stake in shares of Artivion, Inc. (NYSE:AORT) by 3.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,457 shares of the company’s stock after selling 2,208 shares during the quarter. New York State Teachers Retirement System owned 0.15% of Artivion worth $1,786,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. Quarry LP boosted its position in shares of Artivion by 210.8% during the 3rd quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares during the period. R Squared Ltd purchased a new position in shares of Artivion during the fourth quarter worth $39,000. GAMMA Investing LLC boosted its position in shares of Artivion by 21.8% during the fourth quarter. GAMMA Investing LLC now owns 2,772 shares of the company’s stock worth $79,000 after buying an additional 497 shares during the period. KBC Group NV grew its stake in shares of Artivion by 80.4% in the fourth quarter. KBC Group NV now owns 2,813 shares of the company’s stock valued at $80,000 after buying an additional 1,254 shares in the last quarter. Finally, RiverPark Advisors LLC raised its holdings in shares of Artivion by 151.6% in the 3rd quarter. RiverPark Advisors LLC now owns 5,387 shares of the company’s stock valued at $143,000 after buying an additional 3,246 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Jean F. Holloway sold 8,070 shares of Artivion stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total value of $243,068.40. Following the transaction, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at $4,634,323.44. The trade was a 4.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Andrew M. Green sold 7,618 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $30.00, for a total transaction of $228,540.00. Following the completion of the transaction, the vice president now owns 33,503 shares in the company, valued at $1,005,090. This represents a 18.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 20,017 shares of company stock valued at $600,007 in the last three months. 8.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AORT. JMP Securities restated a “market outperform” rating and set a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Oppenheimer raised their price objective on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $34.00 target price on shares of Artivion in a research note on Tuesday, January 28th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $31.80.

Artivion Stock Down 1.8 %

Artivion stock opened at $28.29 on Friday. The stock has a market cap of $1.19 billion, a PE ratio of -1,414.70 and a beta of 1.75. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The stock’s fifty day moving average is $29.77 and its two-hundred day moving average is $27.79. Artivion, Inc. has a 1-year low of $18.38 and a 1-year high of $32.33.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.